JAMES PRATTY: Open Payments
NPI 1528049608 · TORRANCE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$78,299 in 171 payments from 13 companies in 2025. Trend: 2023 $100,910 · 2024 $60,983 · 2025 $78,299
Speaker / faculty: $58,385Travel & lodging: $10,656Consulting: $4,761Food & beverage: $4,386Education: $111
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 42 | $27,105 |
| Vanda Pharmaceuticals Inc. | 43 | $26,239 |
| ABBVIE INC. | 30 | $13,164 |
| Teva Pharmaceuticals USA, Inc. | 17 | $10,822 |
| Alkermes, Inc. | 12 | $303 |
| Luye Pharma (USA) Ltd. | 9 | $227 |
| Janssen Pharmaceuticals, Inc | 10 | $204 |
| E.R. Squibb & Sons, L.L.C. | 3 | $104 |
| Otsuka America Pharmaceutical, Inc. | 1 | $32 |
| Lundbeck LLC | 1 | $32 |
Products named: CAPLYTA, FANAPT, VRAYLAR, AUSTEDO XR, ARISTADA, ERZOFRI EXTENDED-RELEASE, INVEGA SUSTENNA, COBENFY.
Industry payments across CA — which companies pay providers there.
